Gabapentin vs. Pregabalin: Choosing the Right Neuropathic Agent After an Accident

James Wong — Founder & Pharmacist, LienScripts | May 15, 2024 | 7 min read

Gabapentin and pregabalin are the two most commonly prescribed medications for nerve pain after a personal injury. They share the same mechanism of action but differ significantly in absorption, onset, dosing schedule, and regulatory classification. Understanding the clinical differences helps patients and attorneys make sense of why one is prescribed over the other.

Two Medications, One Mechanism

Gabapentin and pregabalin are structurally related compounds that share the same primary mechanism of action: both bind to the alpha-2-delta subunit of voltage-gated calcium channels in the central and peripheral nervous system. By occupying this binding site, they reduce the release of excitatory neurotransmitters — including glutamate, norepinephrine, and substance P — that drive neuropathic pain signaling.

Despite this shared mechanism, the two medications are not interchangeable in clinical practice. Their pharmacokinetic profiles differ in ways that produce meaningfully different clinical experiences — in onset of effect, predictability of dosing, and schedule of administration.

[!KEY] Pregabalin absorbs linearly — doubling the dose doubles the blood level; gabapentin does not. Pregabalin typically produces pain relief in one week vs. 2–4 weeks for gabapentin. Pregabalin is a federal Schedule V controlled substance; gabapentin is not federally scheduled. A documented gabapentin-to-pregabalin escalation demonstrates treatment-refractory neuropathic pain. Both medications are covered under pharmacy liens.

Key Pharmacological Differences

Absorption: Linear vs. Nonlinear

This is the most clinically important pharmacological distinction between the two drugs.

Pregabalin is absorbed linearly. When you double the dose, blood levels approximately double. This predictable dose-response relationship makes titration straightforward — the prescribing physician can increase the dose with confidence about the resulting blood level change.

Gabapentin is absorbed through a saturable transport mechanism in the gastrointestinal tract. At low doses, absorption is efficient. As doses increase, the transporter becomes saturated and a progressively smaller fraction of each dose is absorbed. This means that at higher doses, doubling the dose does not double the blood level — the therapeutic effect plateaus even as the nominal dose continues to climb.

In practical terms: gabapentin requires more careful dosing strategy at higher dose ranges, and patients who are not responding to high-dose gabapentin may respond to pregabalin at its standard therapeutic doses because pregabalin achieves adequate blood levels more reliably.

Onset of Action

Pregabalin typically produces clinically meaningful pain relief within the first week of therapy. Gabapentin generally takes 2–4 weeks to produce comparable benefit, partly because physicians titrate more cautiously at the start.

For a patient who has just been in a serious accident and is dealing with acute-to-subacute neuropathic pain, the difference between one week and four weeks to meaningful relief is clinically significant.

Dosing Schedule

Gabapentin is typically prescribed three times daily (TID) because its half-life and absorption characteristics require more frequent dosing to maintain therapeutic blood levels throughout the day.

Pregabalin is typically prescribed twice daily (BID). For patients managing multiple medications and a busy treatment schedule, twice-daily dosing is more adherence-friendly.

Regulatory Classification

Pregabalin is a Schedule V controlled substance under the federal Controlled Substances Act. This imposes prescription restrictions: it cannot be called in by phone in most states, cannot be refilled without a new prescription in some circumstances, and requires tighter prescribing oversight.

Gabapentin is not scheduled at the federal level. However, several states have independently scheduled gabapentin, and prescribing restrictions vary by jurisdiction. In California, gabapentin is not currently scheduled at the state level, though prescribers are required to query the Controlled Substance Utilization Review and Evaluation System (CURES) before prescribing it.

FDA-Approved Indications

Pregabalin is FDA-approved for:

• Postherpetic neuralgia (PHN)
• Diabetic peripheral neuropathy (DPN)
• Fibromyalgia
• Spinal cord injury-associated neuropathic pain
• Adjunctive therapy for partial-onset seizures

Gabapentin is FDA-approved for:

• Postherpetic neuralgia
• Adjunctive therapy for partial-onset seizures

For most conditions treated in personal injury cases — disc herniation with radiculopathy, post-traumatic neuropathy, CRPS — both medications are used off-label. Pregabalin has the stronger FDA approval for SCI-related neuropathic pain, which is relevant when spinal cord injury is part of the claim. Full prescribing information is available through the FDA: Pregabalin (Lyrica) — FDA Drug Information | Gabapentin (Neurontin) — FDA Drug Information.

How These Medications Are Used in PI Cases

The Gabapentin-First Approach

Many treating physicians start with gabapentin because it is non-scheduled at the federal level, widely familiar, and has a long safety record. When patients respond adequately to gabapentin at reasonable doses, there is no reason to change.

The Escalation to Pregabalin

When gabapentin produces insufficient relief — which is common at higher doses due to the saturable absorption described above — physicians frequently switch to pregabalin. This escalation is clinically appropriate and well-supported by the pharmacological differences between the two drugs.

In PI cases, this escalation creates a clear and documented treatment trajectory in the medical and pharmacy records:

1. Gabapentin prescribed at initiation
2. Dose increases documented over subsequent weeks
3. Inadequate response noted in physician records
4. Transition to pregabalin documented
5. Improved response documented on pregabalin

This escalation narrative supports the argument that the patient's neuropathic pain was severe enough to require progressive pharmacological intervention.

[!KEY] The documented escalation from gabapentin to pregabalin — recorded in both the physician's chart and the pharmacy fill history — is one of the clearest narratives of treatment-refractory neuropathic pain available in a PI case; pull and organize both records together when building the demand package.

[!TIP] For Attorneys: Request the complete pharmacy fill history any time a gabapentin-to-pregabalin switch is documented. Combined with physician notes recording inadequate pain control on gabapentin, this progression demonstrates treatment-refractory neuropathic pain — supporting both injury severity and the medical necessity of the escalated medication at settlement.

When Pregabalin Is Prescribed First

Physicians with experience in PI cases sometimes prescribe pregabalin from the start when:

• The patient's neuropathic pain presentation is severe
• They anticipate a prolonged treatment timeline
• The patient has previously tried gabapentin without adequate relief
• The injury involves spinal cord pathology where pregabalin has stronger evidence

Pharmacy Lien Coverage for Both Medications

Both gabapentin and pregabalin are covered under pharmacy liens with LienScripts when prescribed by a treating physician for injury-related neuropathic pain. Both are available in generic form and accessible through pharmacy lien programs.

The pharmacy dispensing record for either medication — or for the escalation from one to the other — is documentation of a clinical treatment decision that reflects the severity and persistence of the patient's nerve pain.

[!KEY] Because pregabalin is a Schedule V controlled substance, a prescribing physician must make a deliberate documented clinical decision to select it over non-scheduled gabapentin — this prescribing choice itself serves as independent clinical evidence that the patient's neuropathic pain was assessed as requiring the more controlled, more potent therapeutic option.

For further clinical background, see the NIH MedlinePlus overview of gabapentin and the NIH MedlinePlus overview of pregabalin.

To learn how pharmacy lien coverage works for your neuropathic pain medications, visit for patients.

Related Resources

• Gabapentin for Personal Injury Cases: Attorney's Guide — Clinical guide to gabapentin's role in PI cases and how it supports medical necessity